The safety and efficacy of osimertinib for the treatment ofEGFRT790M mutation positive non-small-cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The safety and efficacy of osimertinib for the treatment ofEGFRT790M mutation positive non-small-cell lung cancer

Published:2016-03-21 Issue:4 Volume:16 Page:383-390
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Gao Xin,Le Xiuning,Costa Daniel B.

Funder

American Cancer Society

International Association for the Study of Lung Cancer

National Cancer Institute

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

http://www.tandfonline.com/doi/pdf/10.1586/14737140.2016.1162103

Reference56 articles.

1. A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

2. Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers

3. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

4. Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer

5. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the structural activity relationship of the Osimertinib: A covalent inhibitor of double mutant EGFRL858R/T790M tyrosine kinase for the treatment of Non-Small Cell Lung Cancer (NSCLC);Bioorganic & Medicinal Chemistry;2024-07

2. Design, synthesis and biological evaluation of potent epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors against resistance mutation for lung cancer treatment;Bioorganic Chemistry;2024-02

3. Clinical Trials for Oral, Inhaled and Intravenous Drug Delivery System for Lung Cancer and Emerging Nanomedicine-Based Approaches;International Journal of Nanomedicine;2023-12

4. Osimertinib Induces the Opposite Effect of Proliferation and Migration in the Drug Resistance of EGFR-T790M Non-small Cell Lung Cancer Cells;Anti-Cancer Agents in Medicinal Chemistry;2023-07

5. The potential of phytochemicals against epidermal growth factor receptor tyrosine kinase (EGFRK): an insight from molecular dynamic simulations;Journal of Biomolecular Structure and Dynamics;2023-05-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3